### Highlights of This Issue 2193

#### SPECIAL FEATURES

**CCR 20th Anniversary Commentary**

2195  
**CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio**  
Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

2198  
**CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy**  
Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

**CCR Translations**

2201  
**A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2**  
Yanping Xiao and Gordon J. Freeman  
*See related article, p. 2359*

2204  
**Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"**  
Lisa M. Rimsza  
*See related article, p. 2367*

**Molecular Pathways**

2207  
**Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells**  
Hiba Ahmad Zahreddine and Katherine L.B. Borden

**CCR Focus**

2212  
**Quit Early, Quit Often**  
Susan E. Bates

2213  
**Lung Cancer in the Era of Precision Medicine**  
Katerina Politi and Roy S. Herbst

2221  
**EGFR: The Paradigm of an Oncogene-Driven Lung Cancer**  
Gregory J. Riely and Helena A. Yu

2227  
**Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine**  
Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw

2236  
**Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics**  
David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

2244  
**Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?**  
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

2256  
**Immune Checkpoint Modulation for Non–Small Cell Lung Cancer**  
Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

**Special Report**

2263  
**Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care**  
Edward Abrahams, Margaret Foti, and Marcia A. Kean

**CANCER THERAPY: CLINICAL**

2268  
**Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer**  
Shinichi Kageyama, Hiroaki Ikeda, Yoshihiro Miyahara, Naoko Imai, Mikiyoshi Ishihara, Kanako Saito, Sahoko Sugino, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi, Naoki Inoue, Masahide Tanabe, Tomohide Kidokoro, Hirofumi Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, and Hiroshi Shiku

2278  
**Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma**  
### Table of Contents

- **2289** Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

- **2297** The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
  - Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Hellomans, Johann S. de Bono, and Ferry A.L.M. Eskens

- **2305** Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
  - Lawrence G. Lum, Archan Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dixon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

### PERSONALIZED MEDICINE AND IMAGING

- **2315** Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

### CANCER THERAPY: PRECLINICAL

- **2325** Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
  - Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Etkin, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

- **2338** Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
  - Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbana, Govind Panchamoomthy, Dikshi Gupta, Harpal Singh, Surender Kharbana, and Donald Kufe

- **2348** Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
  - Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Srihari Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Kriptsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

### BIOLOGY OF HUMAN TUMORS

- **2359** Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
  - Murali Janakiram, Jordan M. Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohaegbulam, Ruihui Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang

- **2367** Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System

- **2379** Molecular Changes Associated with Acquired Resistance to Crizotinib in ROSI-Rearranged Non–Small Cell Lung Cancer
  - Alnain Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

- **2388** Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
  - Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Elke Vettorazzi, Gabi Vohwinkel, Marianne Klokow, Roswitha Uibeleisen, Patrick Ehm, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jucker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

- **2399** miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
  - Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdi, Lugui Qiu, and Hong Chang

### CORRECTION

- **2412** Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.